Table 2.
Baseline characteristics and laboratory results of patients with ACLF and without ACLF
| Variables | ACLF n = 69 (34.0%) | NO ACLF n = 134 (66.0%) | P value |
|---|---|---|---|
| Demographics data | |||
| Age(years), M ± SD | 55.4 ± 13.7 | 57.9 ± 13.7 | 0.23 |
| Sex m/f (% male) | 52 (75.4%) | 86 (64.2%) | 0.12 |
| Complications of cirrhosis | |||
| Ascites n (%) | 60 (87.0%) | 99 (73.9%) | 0.03 |
| Variceal bleeding n (%) | 23 (33.3%) | 29 (21.6%) | 0.09 |
| Spontaneous bacterial peritonitis n (%) | 11 (15.9%) | 18 (13.4%) | 0.67 |
| Hepatorenal syndrome n (%) | 23 (33.3%) | 4 (3.0%) | <0.001 |
| HE n (%) | 22 (31.9%) | 9 (6.7%) | <0.001 |
| Laboratory and radiographic findings | |||
| White blood cell count, 109 cells/L | 13.8 (8.65–21.95) | 8.1 (4.7–11.6) | <0.001 |
| Platelet count, 109 platelets/L (IQR) | 47 (22–75.5) | 68.5 (40.8–101.5) | 0.001 |
| C-reactive protein level, mg/dL (IQR) | 28.8 (14.7–72.0) | 26.9 (11.6–65.5) | 0.38 |
| Creatinine, μmol/L (IQR) | 154.0 (83.5–256.5) | 66.5 (53.8–80.0) | <0.001 |
| Albumin, g/dL (M ± SD) | 24.8 ± 4.8 | 26.2 ± 4.9 | 0.06 |
| Total Bilirubin, mg/dL (IQR) | 252.0 (62.5–470.5) | 38.0 (22.0–99.5) | <0.001 |
| INR (IQR) | 2.37 (1.62–3.38) | 1.39 (1.22–1.73) | <0.001 |
| Multi-lobar infiltration n (%) | 55 (80.9%) | 100 (75.8%) | 0.48 |
| SIRS n (%) | 53 (76.8%) | 68 (50.7%) | <0.001 |
| ICU addmission n (%) | 24 (35.3%) | 8 (6.0%) | <0.001 |
| EASL-CLIF definition ACLF | |||
| ACLF-1 (%) | 13 (18.8%) | ||
| ACLF-2 (%) | 28 (40.6%) | ||
| ACLF-3 (%) | 28 (40.6%) | ||
| PSI score (IQR) | 159 (117–195) | 96 (86–115) | <0.001 |
| Mortality | |||
| 30-day mortality | 32 (46.4%) | 6 (4.5%) | <0.001 |
| 90-day mortality | 48 (69.6%) | 15 (11.2%) | <0.001 |